JP2005508322A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508322A5
JP2005508322A5 JP2003530213A JP2003530213A JP2005508322A5 JP 2005508322 A5 JP2005508322 A5 JP 2005508322A5 JP 2003530213 A JP2003530213 A JP 2003530213A JP 2003530213 A JP2003530213 A JP 2003530213A JP 2005508322 A5 JP2005508322 A5 JP 2005508322A5
Authority
JP
Japan
Prior art keywords
suramin
agent
interleukin
kit
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/030210 external-priority patent/WO2003026574A2/en
Publication of JP2005508322A publication Critical patent/JP2005508322A/ja
Publication of JP2005508322A5 publication Critical patent/JP2005508322A5/ja
Pending legal-status Critical Current

Links

JP2003530213A 2001-09-24 2002-09-24 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分 Pending JP2005508322A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32470401P 2001-09-24 2001-09-24
PCT/US2002/030210 WO2003026574A2 (en) 2001-09-24 2002-09-24 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

Publications (2)

Publication Number Publication Date
JP2005508322A JP2005508322A (ja) 2005-03-31
JP2005508322A5 true JP2005508322A5 (https=) 2006-01-12

Family

ID=23264730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530213A Pending JP2005508322A (ja) 2001-09-24 2002-09-24 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分

Country Status (9)

Country Link
US (2) US20040180955A1 (https=)
EP (1) EP1429713A4 (https=)
JP (1) JP2005508322A (https=)
KR (1) KR20040062546A (https=)
CN (1) CN100441176C (https=)
AU (1) AU2002330088B2 (https=)
CA (1) CA2461227C (https=)
IL (1) IL161036A0 (https=)
WO (1) WO2003026574A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
JP2022145629A (ja) * 2021-03-18 2022-10-04 学校法人産業医科大学 スラミンを含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
NZ337376A (en) * 1997-03-11 2002-02-01 Aeterna Lab Inc Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Similar Documents

Publication Publication Date Title
JP2005508322A5 (https=)
JP5846822B2 (ja) 栄養又は治療組成物
CA2461227A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
Johnson Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies
JP2017519753A5 (https=)
US5854231A (en) Pharmaceutical composition for inhibiting the growth of cancers
CA2503730A1 (en) Cytarabine monophosphate prodrugs
ES2738983T3 (es) Composición y procedimiento para la administración segura y eficaz de halopiruvato para el tratamiento del cáncer
RU2016133168A (ru) Изоксазолиновые композиции и их применение в качестве противопаразитарных средств
RU2006146619A (ru) Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr)
JP2006507308A5 (https=)
JP2010533206A5 (https=)
AU2010208062B2 (en) Compositions and methods for the treatment of cancer
RU2003108822A (ru) Улучшенная противоопухолевая композиция на основе паклитаксела
RU2005114018A (ru) Эпотилон d+фторурацил/гемцитабин
JP2004501870A5 (https=)
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
JP2009511590A5 (https=)
JPWO2007108272A1 (ja) 癌治療用キットおよび癌治療用医薬組成物
US20050203174A1 (en) Combination therapies using leptomycin B
JP2003526667A5 (https=)
KR100812693B1 (ko) 항종양 효과 증강제 및 항종양제
JPH0586376B2 (https=)
CZ2003909A3 (cs) Léčivo pro léčení nádorů obsahující distamycinové deriváty
CN1615136A (zh) 包含埃坡霉素和抗代谢物的组合